Mutant p53 expression: A marker of diminished survival in well- differentiated soft tissue sarcoma

Tina J Hieken, Tapas K. Das Gupta

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The aim of this study was to assess the translational value of the quantitative assay of mutant p53 protein expression as both a prognostic indicator and a tool to determine appropriate therapy in a group of relatively innocuous and morphologically similar soft tissue sarcomas (STSs). Using a quantitative ELISA, we analyzed mutant p53 protein expression in 47 well-differentiated (grade I) STSs from patients treated in our Department of Surgical Oncology. Sixteen of 47 tumors expressed up to 42.6 ng mutant p53 protein/mg total protein. After a mean follow-up of 112 months, 63% of the patients with mutant p53+ tumors but only 16% of the patients with mutant p53-tumors had died (P < 0.01). Mutant p53 expression of ≤4.5 ng predicted even greater reduction in survival. These data show that mutant p53 expression identifies biologically aggressive grade 1 STSs. This molecular marker should have translational value as a tool to select those patients likely to benefit from aggressive multimodal therapy and intense surveillance.

Original languageEnglish (US)
Pages (from-to)1391-1395
Number of pages5
JournalClinical Cancer Research
Volume2
Issue number8
StatePublished - Aug 1996
Externally publishedYes

Fingerprint

Sarcoma
Mutant Proteins
Survival
Neoplasms
Enzyme-Linked Immunosorbent Assay
Therapeutics
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mutant p53 expression : A marker of diminished survival in well- differentiated soft tissue sarcoma. / Hieken, Tina J; Das Gupta, Tapas K.

In: Clinical Cancer Research, Vol. 2, No. 8, 08.1996, p. 1391-1395.

Research output: Contribution to journalArticle

@article{6f689315d7a849e2966fa151c211be60,
title = "Mutant p53 expression: A marker of diminished survival in well- differentiated soft tissue sarcoma",
abstract = "The aim of this study was to assess the translational value of the quantitative assay of mutant p53 protein expression as both a prognostic indicator and a tool to determine appropriate therapy in a group of relatively innocuous and morphologically similar soft tissue sarcomas (STSs). Using a quantitative ELISA, we analyzed mutant p53 protein expression in 47 well-differentiated (grade I) STSs from patients treated in our Department of Surgical Oncology. Sixteen of 47 tumors expressed up to 42.6 ng mutant p53 protein/mg total protein. After a mean follow-up of 112 months, 63{\%} of the patients with mutant p53+ tumors but only 16{\%} of the patients with mutant p53-tumors had died (P < 0.01). Mutant p53 expression of ≤4.5 ng predicted even greater reduction in survival. These data show that mutant p53 expression identifies biologically aggressive grade 1 STSs. This molecular marker should have translational value as a tool to select those patients likely to benefit from aggressive multimodal therapy and intense surveillance.",
author = "Hieken, {Tina J} and {Das Gupta}, {Tapas K.}",
year = "1996",
month = "8",
language = "English (US)",
volume = "2",
pages = "1391--1395",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Mutant p53 expression

T2 - A marker of diminished survival in well- differentiated soft tissue sarcoma

AU - Hieken, Tina J

AU - Das Gupta, Tapas K.

PY - 1996/8

Y1 - 1996/8

N2 - The aim of this study was to assess the translational value of the quantitative assay of mutant p53 protein expression as both a prognostic indicator and a tool to determine appropriate therapy in a group of relatively innocuous and morphologically similar soft tissue sarcomas (STSs). Using a quantitative ELISA, we analyzed mutant p53 protein expression in 47 well-differentiated (grade I) STSs from patients treated in our Department of Surgical Oncology. Sixteen of 47 tumors expressed up to 42.6 ng mutant p53 protein/mg total protein. After a mean follow-up of 112 months, 63% of the patients with mutant p53+ tumors but only 16% of the patients with mutant p53-tumors had died (P < 0.01). Mutant p53 expression of ≤4.5 ng predicted even greater reduction in survival. These data show that mutant p53 expression identifies biologically aggressive grade 1 STSs. This molecular marker should have translational value as a tool to select those patients likely to benefit from aggressive multimodal therapy and intense surveillance.

AB - The aim of this study was to assess the translational value of the quantitative assay of mutant p53 protein expression as both a prognostic indicator and a tool to determine appropriate therapy in a group of relatively innocuous and morphologically similar soft tissue sarcomas (STSs). Using a quantitative ELISA, we analyzed mutant p53 protein expression in 47 well-differentiated (grade I) STSs from patients treated in our Department of Surgical Oncology. Sixteen of 47 tumors expressed up to 42.6 ng mutant p53 protein/mg total protein. After a mean follow-up of 112 months, 63% of the patients with mutant p53+ tumors but only 16% of the patients with mutant p53-tumors had died (P < 0.01). Mutant p53 expression of ≤4.5 ng predicted even greater reduction in survival. These data show that mutant p53 expression identifies biologically aggressive grade 1 STSs. This molecular marker should have translational value as a tool to select those patients likely to benefit from aggressive multimodal therapy and intense surveillance.

UR - http://www.scopus.com/inward/record.url?scp=0029760533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029760533&partnerID=8YFLogxK

M3 - Article

C2 - 9816312

AN - SCOPUS:0029760533

VL - 2

SP - 1391

EP - 1395

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -